TriangleCARE T cells (NCT04715191)
CARE T cells trial for Liver Cancer (NCT04715191). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Some childhood solid tumors, liver cancer, rhabdomyosarcoma, Wilms tumor, share a surface protein called glypican-3. When those cancers return after surgery and chemotherapy, cures are rare.
The idea: aim engineered T cells at that shared protein, and arm them so they survive inside a solid tumor.
CAR T cells often stall in solid tumors, where they run out of support. At Texas Children's, a child's T cells receive a receptor for glypican-3 plus genes for two growth signals, interleukin-15 and interleukin-21, so the cells carry their own fuel. After three days of chemotherapy makes room, they are infused once.
A dose-finding trial, ages one to twenty-one, for tumors that test positive for the protein. David Steffin leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.